Acrobiosystems Co

Acrobiosystems Co Inventory

The Inventory of Acrobiosystems Co (301080.SZ) as of Nov 16, 2026 is 263.74 M CNY. In the previous year, Inventory was 197.13 M CNY — a change of 33.79% (higher).

Inventory

263.74 MCNY

YoY

33.79%

Last updated:

Inventory of Acrobiosystems Co is 2025 263.74 M CNY. Inventory of Acrobiosystems Co was 2024 197.13 M CNY. It decreases by 33.79% higher compared to the previous year.

The Acrobiosystems Co Inventory history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Inventory
Date
Inventory
Jan 1, 2018
16.93 M CNY
Jan 1, 2019
21.57 M CNY
Jan 1, 2020
32.58 M CNY
Jan 1, 2021
62.17 M CNY
Jan 1, 2022
93.05 M CNY
Jan 1, 2023
136.72 M CNY
Jan 1, 2024
197.13 M CNY
Jan 1, 2025
263.74 M CNY
The Acrobiosystems Co Inventory history
YEARInventoryYoY
263.74 MCNY+33.79%
197.13 MCNY+44.19%
136.72 MCNY+46.93%
93.05 MCNY+49.66%
62.17 MCNY+90.81%
32.58 MCNY+51.07%
21.57 MCNY+27.43%
16.93 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Inventory of Acrobiosystems Co is 263.74 M CNY in 2025.

Inventory of Acrobiosystems Co changed from 197.13 M CNY to 263.74 M CNY, representing a 33.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Inventory Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Inventory includes raw materials, work-in-progress, and finished goods. Efficient inventory management is crucial for profitability.

Inventory's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Inventory's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co